Further large-scale prospective investigations will be necessary in order to validate the effect of systemic inflammation on breast cancer prognosis as well as the potential clinical implementation of pre-operative CRP level as a prognostic biomarker in node-negative breast cancer. This evidence concerns the gene CRP and breast cancer.